Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Accumulated Expenses (2021 - 2025)

Historic Accumulated Expenses for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to $19.5 million.

  • Amylyx Pharmaceuticals' Accumulated Expenses fell 6140.99% to $19.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.5 million, marking a year-over-year decrease of 6140.99%. This contributed to the annual value of $23.9 million for FY2024, which is 5851.12% down from last year.
  • As of Q3 2025, Amylyx Pharmaceuticals' Accumulated Expenses stood at $19.5 million, which was down 6140.99% from $17.5 million recorded in Q2 2025.
  • In the past 5 years, Amylyx Pharmaceuticals' Accumulated Expenses ranged from a high of $67.9 million in Q1 2024 and a low of $12.1 million during Q1 2025
  • For the 5-year period, Amylyx Pharmaceuticals' Accumulated Expenses averaged around $33.3 million, with its median value being $30.5 million (2023).
  • Per our database at Business Quant, Amylyx Pharmaceuticals' Accumulated Expenses surged by 19416.46% in 2022 and then plummeted by 8222.15% in 2025.
  • Quarter analysis of 5 years shows Amylyx Pharmaceuticals' Accumulated Expenses stood at $13.0 million in 2021, then soared by 194.16% to $38.3 million in 2022, then skyrocketed by 50.67% to $57.7 million in 2023, then plummeted by 58.51% to $23.9 million in 2024, then fell by 18.7% to $19.5 million in 2025.
  • Its Accumulated Expenses stands at $19.5 million for Q3 2025, versus $17.5 million for Q2 2025 and $12.1 million for Q1 2025.